Dr. Daniel Tang joined the advisory board of BOCG in May 2024. Dr. Daniel Tang was CEO of Shanghai NK CellTech, responsible for overall operation of the company. Prior to this he was the founding CEO for Thororna Inc, a biotech company focusing on innovative circular RNA technology on Covid-19 vaccine, rare diseases and cancer vaccines. Within a year he led the team to complete three rounds fund raising, raising more than 430 mil RMB. Before Thororna, he was COO of Phanes Therapeutics and was a key member of its management team.  He involved raising 120 mil RMB fund and licensing out deals for two products.

Dr. Tang was leaders in other global and domestic companies with increasing responsibilities. He was CEO for UPP, GM for ICON Clinical Research in APAC, SVP for Frontage, VP for ChemPartner. He also worked for Pfizer and DuPont in US as senior principal scientist. Dr. Tang received his BS in Biochemistry from Peking University, PhD from George Washington University and MBA from University of Michigan.